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Abstract
Non-alcoholic fatty liver disease (NAFLD) is defined as fat accumulation in the liver, ranging from
simple steatosis to non-alcoholic steatohepatitis (NASH). Although it used to be considered a benign
condition, nowadays it is known to be associated with liver injury and the development of end-stage
liver disease. NAFLD is the hepatic manifestation of metabolic syndrome (MS) with an incidence
rising in accordance with the increased prevalence of MS, the latter being considered the most
common cause of liver enzyme elevation in Western countries. To date, no medications or surgical
procedures have been approved for effective treatment of NAFLD, and all of the therapies tested so
far must still be regarded as experimental. It is expected that, based on the large amount of data
producedinthelastfewyearsandtheongoinglargemulticenterclinicaltrials,theeffectivetreatment(s)
for NASH will soon be defined. Meanwhile, lifestyle interventions and behavior therapy, the only
treatmentsshowntobeeffective,mustbeintroducedindailyclinicalpracticeand,ifpossible,supported
by public health programs.
Introduction and context
Although non-alcoholic fatty liver disease (NAFLD) was
first described byZelman [1] more than 65 yearsago, only
in 1980 did Ludwig and colleagues [2] define a new entity
characterized by a type of fatty liver with inflammation,
ballooned hepatocytes, and fibrosis, naming it ‘non-
alcoholic steatohepatitis’ (NASH). NAFLD is now defined
as fat accumulation in the liver exceeding 5-10% by
weight in subjects without significant alcohol consump-
tion (<20 g/day, the equivalent of less than two or three
glasses of wine per day) and without any other known
causes of chronic liver disease. In clinical practice, the
diagnosisofNAFLDisusuallyreachedbyultrasonography
that allows the detection of moderate to severe steatosis
with a fair sensitivity and specificity, but only when fat on
the liver biopsy exceeds 20-30%.
NAFLD and NASH are strictly correlated with the
presence of insulin resistance (IR), which is often
associated with central obesity, type 2 diabetes, and
dyslipidemia, rendering liver steatosis the hepatic
manifestation of metabolic syndrome (MS). The inci-
dence of NAFLD/NASH is rapidly rising in adults and
children due to the increased prevalence of obesity,
type 2 diabetes, and metabolic diseases, and is now
considered the most frequent cause of elevated liver
enzymes [3,4].
Population studies estimate that 20-25% of adults have
NAFLD, and about 10% may progress to NASH,
cirrhosis, and ultimately hepatocellular carcinoma over
a period of 30-40 years [5]. In contrast, the overall
survival due to increased risk for both cardiovascular and
liver disease mortality is lower [6,7]. Since hepatologists
worldwide are facing an epidemiological explosion of
this disease, several efforts are aimed at the early
identification of subjects affected by NAFLD/NASH and
at finding an effective treatment.
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Progress in developing potential therapies for NAFLD/
NASH has been made mainly by addressing the singular
stepinvolvedinthepathogenesisofthediseases(Figure1).
Agents reducing oxidative stress and/or apoptosis or
showing cytoprotective properties have been evaluated
with inconclusive results since the studies were conducted
in small uncontrolled trials. At present, lifestyle interven-
tions and behavior therapy, together with drugs used to
treat the associated components of the MS (hypertension,
diabetes, or dyslipidemia), represent the only therapeutic
approach available to the clinician.
Lifestyle modifications
Lifestyle modifications through a multidisciplinary
approach, including dietary intervention, behavior
therapy, and physical exercise, are the frontline therapy
for this disease [8]. This is true not only in obese or
overweight patients but also in normal-weight patients
with cryptogenic NASH demonstrated by liver biopsy.
Even though this approach could be ultimately cost-
effective, it unfortunately is limited by the long-term
compliance of the patients. Dietary intervention
together with daily physical exercise is associated with
a weight reduction and amelioration of IR and steatosis
Figure 1. Treatment targets according to the pathogenesis mechanisms of NAFLD and NASH
Pathogenesis mechanisms (dark blue) of NAFLD and NASH and various treatment options (yellow) are displayed. Treatment targets are indicated by the pink
arrows. IL-6, interleukin-6; IR, insulin resistance; MCP-1, monocyte chemoattractant protein-1; NAFLD, non-alcoholic fatty liver disease; NASH,
non-alcoholic steatohepatitis; PDGF, platelet-derived growth factor; SAMe, S-adenosylmethionine; TGF, transforming growth factor; UDCA, ursodeoxycholic
acid; VLDL, very low density lipoproteins.
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more recently Harrison and Day [11] demonstrated that
reducing weight by at least 5%, with subsequent weight
control and regular exercise, improves or normalizes
alanine aminotransferase (ALT) levels [12]; a reduction
of body weight of more than 9% is associated with an
improvement in hepatic histology [11,13]. Modifica-
tions of diet to improve NAFLD or avoid the progres-
sion to NASH have been attempted recently in pilot
studies and included both the reduction of saturated
fatty acids and simple carbohydrate intake and the
increase of polyunsaturated fatty acids and slowly
adsorbed carbohydrates [14,15]. Much-needed larger
trials with appropriate histological follow-up are still
lacking.
Pharmacotherapy
Oral hypoglycemic agents
Insulin-sensitizing agents, namely metformin and the
thiazolidinediones (TZDs) (also called glitazones), have
been investigated in controlled trials. Many studies
demonstrated an improvement of aminotransferase
levels, IR, and histology after metformin treatment
[16]. More recently, metformin has been found to
modulate the expression of the pro-inflammatory
tumor necrosis factor-alpha (TNF-a) cytokines [17] and
to improve liver function and ecographic steatosis more
than dietary modifications alone [18]. Also, TZDs
(pioglitazone and rosiglitazone) are proving promising
in the treatment of NASH, and various randomized long-
term controlled studies in limited series have demon-
strated a significant reduction in serum ALT and liver fat
content associated with an improvement of IR and liver
histology [19]. However, the main limitations of TZD
therapy are the short duration of the beneficial effects
after the drug is stopped and its contraindication in
patients with heart disease [20]. Further larger studies are
required.
Weight-loss drugs
Contradictory data have been published on the treat-
ment of NASH with orlistat, a lipase inhibitor reducing
fat absorption. In randomized placebo-controlled trials,
orlistat led to an improvement in serum liver enzymes,
ultrasound findings, and hepatic inflammation and
fibrosis, but only in patients who maintained a
significant weight reduction [21]. In another pilot
study, which compared orlistat and sibutramine (an
enhancer of satiety), it was demonstrated that treatment
with both drugs led to liver enzyme improvement and
liver fat reduction at ultrasound [22]. These data suggest
a possible role of orlistat for NASH treatment in
facilitating significant weight loss.
The endocannabinoid (EC) system, involved in the
regulation of food intake and body weight, represents a
novel target for medical therapy of NASH (Figure 1).
Rimonabant is a selective EC CB1 receptor antagonist
decreasing hepatic lipogenesis and increasing satiety,
adiponectin levels, and glucose uptake, thereby improv-
ing insulin levels and lipid profiles. In four large
randomized placebo-controlled multicenter trials, rimo-
nabant has been shown after 1 or 2 years of therapy to
induce a greater significant average weight loss than
placebo in obese patients, and more notably, a sig-
nificant improvement in serum lipid profile, glycosy-
lated hemoglobin, adiponectin, and C-reactive protein in
patients with hyperlipidemia and diabetes. These
impressive metabolic effects and preliminary animal
studies, along with isolated case reports, suggested a
direct effect of this medication on NASH and, in 2007,
prompted two large multicenter trials. Unfortunately,
both trials were interrupted by either American or
European national medicine authorities (the US Food
and Drug Administration and the European Medicine
Agency, respectively) due to the development of sig-
nificant psychiatric problems (severe depression and
suicide) in some patients involved in the trial.
Statins
The role of statins in the treatment of NASH remains
unclear. Recently, it was shown that patients treated with
statins had a significant reduction in hepatic steatosis,
liver enzymes, and TNF-a serum levels, and probably a
low rate of fibrosis progression as well [23]. Although
these early studies suggest that statins may be useful in
hyperlipidemic NAFLD patients, controlled trials are
necessary to validate these results.
Anti-oxidants, cytoprotective agents, and other drugs
Vitamin E, betaine, and ursodeoxycholic acid (UDCA)
therapies have produced controversial results. Studies
usingvitaminEshowedanimprovementofliverfunction
whereas others did not [24,25]. Despite the preliminary
results ofsomepilotstudiesdemonstratingtheprotective
role of UDCA in NAFLD, a large multicenter trial with a
sufficiently large number of patients treated with UDCA
or placebo for 2 years showed histological improvement
in both the UDCA group and the placebo group [26]. It is
possible that UDCA used in combination with other
medications, as in the case of vitamin E, may improve
liver function in NAFLD-affected patients [27].
Betaine, a metabolite that increases levels of S-adeno-
sylmethionine, was used in a small uncontrolled study
demonstrating an improvement in aminotransferase
levels, steatosis, inflammation, and fibrosis after 1 year
of treatment [28]. In two small studies, treatment with
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ments in liver histology [29]. However, the very limited
number of patients involved in these studies renders the
results questionable.
Bariatric surgery
Bariatric surgery is suitable in severely obese patients,
often affected by NAFLD, who failed to lose weight with
nutritional counseling. Different surgical approaches are
possible, and in general, liver histology improves
significantly after bariatric surgery [30].
Implications for clinical practice
The epidemiological explosion of obesity and diabetes in
Western countries led to a parallel increase in the
prevalence of NAFLD. Once the presence of fatty liver
at ultrasound is recognized, it is important for the
general practitioner and the hepatologist to consider
NAFLD as a possible progressive liver disease, signifi-
cantly associated with increased cardiovascular risks,
which must be checked. Physicians have to exclude
alcohol intake and to follow up NAFLD-affected patients
to reduce the progression to NASH and other end-stage
liver diseases. Despite its limitations, liver biopsy is still
the gold standard for the diagnosis of NASH.
Once the diagnosis of NAFLD or NASH is reached, the
main efforts must be focused on changing the lifestyle
of the patient. Diet and physical exercise, which ideally
should always be tailored to the individual, represent
the only therapeutic approach available at present to treat
NASH, by preventing cardiovascular risk and MS manifes-
tations. This therapy needs a strong multidisciplinary
counseling program to increase and maintain patient
compliance.Enrolledpatientsshouldbereferredtotrained
lifestyle therapists (dietitians, behavioral psychologists,
physical activity supervisors, and case managers), and
change in their social environment should be considered.
Other pharmacological or surgical treatments may be
considered but only in patients with associated MS or
severe obesity since no drugs or surgical procedures have
been approved for the treatment of NAFLD or NASH.
Larger multicenter clinical trials and validation studies
are ongoing worldwide (Table 1), and the ideal
treatment for NASH will hopefully be found soon.
Meanwhile, lifestyle interventions and behavior therapy
must be introduced in clinical practice, possibly sup-
ported by public health programs, to change the
environment of our ‘fatty society’.
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Table 1. Promising agents and ongoing clinical trials [31] to treat NASH
Phase II study Phase III study
Therapeutic target Agent Pilot Multicenter Single Multicenter
Weight loss Orlistat ×
Rosiglitazone versus rosiglitazone and metformin versus
rosiglitazone and losartan
×
NASH, non-alcoholic steatohepatitis; PDE4, phosphodiesterase-4; PIVENS, Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic
Patients with Non-alcoholic Steatohepatitis; SAMe, S-adenosylmethionine; TONIC, Treatment of Non-alcoholic Fatty Liver Disease in Children.
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Diet Macronutrients Omega-3 fatty acids ×
Polyunsaturated fatty acids ×
Rimonabant ×
Antioxidants Silymarin ×
Pentoxifilline ×
Pentoxifilline versus pioglitazone ×
SAMe ×
Iron depletion ×
Mitochondrial protection (TRO19662) ×
Inflammation and fibrosis PDE4 inhibitor ×
Reduction of insulin resistance Metformin versus vitamin E versus placebo (TONIC) ×
Pioglitazone versus metformin versus placebo (PIVENS) ×References
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